Pharma funds a good contra bet only if investor holds them for 3-5 years

They have yielded meagre returns of only 4.90 per cent compounded annually over the past five years

Fund, money, investment
Photo: Shutterstock
Business Standard
1 min read Last Updated : Jul 18 2019 | 2:34 AM IST
Are pharma funds a good contra bet?
 
Pharma funds have been laggards over the past year, with a category average return of a meagre 1.74 per cent. They have also yielded meagre returns of only 4.90 per cent compounded annually over the past five years.

However, experts say these funds can prove to be good contra bets for investors willing to hold them for three-five years. One good reason for investing now is that the negatives are already factored into the prices. Indian companies have got better at handling USFDA strictures.

Moreover, Indian pharma companies are global leaders in generics. One in every three generic pill consumed in the US is supplied by an Indian company. And now they are also venturing into complex generics.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Tipping Point

Next Story